GPCR insider transaction filings
Structure Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen GPCR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 11,817 @ $0.34 · Conversion (C): 11,817 @ $0 · Option exercise (M): 11,817 (derivative) @ $0 · Conversion (C): 3,939 (derivative) @ $0 · Sale (S): 3,020 (derivative) @ $53.13 · Sale (S): 519 (derivative) @ $54.20 · +1 more | EDGAR |
| 2026-08-07 | 4 | Berrios John Joseph — Chief Commercial Officer | Grant/award (A): 140,766 @ $0 · Grant/award (A): 174,612 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 11,817 @ $0.34 · Conversion (C): 11,817 @ $0 · Option exercise (M): 11,817 (derivative) @ $0 · Conversion (C): 3,939 (derivative) @ $0 · Sale (S): 3,100 (derivative) @ $49.29 · Sale (S): 839 (derivative) @ $50.03 | EDGAR |
| 2026-07-24 | 4 | FMR LLC — 10% owner | Sale (S): 1,367 (derivative) @ $50.07 · Sale (S): 16,085 (derivative) @ $50.07 | EDGAR |
| 2026-07-15 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 23,634 @ $0.34 · Conversion (C): 23,634 @ $0 · Option exercise (M): 23,634 (derivative) @ $0 · Conversion (C): 7,878 (derivative) @ $0 · Sale (S): 6,278 (derivative) @ $50.80 · Sale (S): 1,600 (derivative) @ $51.71 | EDGAR |
| 2026-06-29 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Option exercise (M): 23,634 @ $0.34 · Conversion (C): 23,634 @ $0 · Option exercise (M): 23,634 (derivative) @ $0 · Conversion (C): 7,878 (derivative) @ $0 · Sale (S): 7,878 (derivative) @ $49.08 | EDGAR |
| 2026-06-18 | 4 | Waldstreicher Joanne — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Russell Angus C. — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | TETLOW SHARON — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | WELCH DANIEL G — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | DOBMEIER ERIC — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | LOVE TED W — Director | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Lang Matthew — COO & GC | Grant/award (A): 184,614 @ $0 · Grant/award (A): 223,776 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | FMR LLC — 10% owner | Sale (S): 1,367 (derivative) @ $55.07 · Sale (S): 16,085 (derivative) @ $55.07 | EDGAR |
| 2026-03-23 | 4 | Coll Crespo Blas — CHIEF MEDICAL OFFICER | Grant/award (A): 75,897 @ $0 · Grant/award (A): 93,984 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Ma Yingli — CHIEF TECHNOLOGY OFFICER | Grant/award (A): 32,526 @ $0 · Grant/award (A): 40,278 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 43,368 @ $0 · Grant/award (A): 53,703 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Yoon Jun — CHIEF FINANCIAL OFFICER | Grant/award (A): 104,085 @ $0 · Grant/award (A): 128,892 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Hall Ashley — Chief Development Officer | Grant/award (A): 47,706 @ $0 · Grant/award (A): 59,073 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Stevens Raymond C — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 260,217 @ $0 · Grant/award (A): 322,230 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Coll Crespo Blas — CHIEF MEDICAL OFFICER | Tax withholding (F): 11,826 @ $20.99 | EDGAR |
| 2026-03-05 | 4 | Ma Yingli — CHIEF TECHNOLOGY OFFICER | Tax withholding (F): 11,313 @ $20.99 | EDGAR |
| 2026-03-05 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 18,735 @ $20.99 | EDGAR |
| 2026-03-05 | 4 | Yoon Jun — CHIEF FINANCIAL OFFICER | Tax withholding (F): 22,305 @ $20.99 | EDGAR |
| 2026-03-05 | 4 | Hall Ashley — Chief Development Officer | Tax withholding (F): 4,836 @ $20.99 · Grant/award (A): 225 (derivative) @ $0 · Grant/award (A): 237 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Stevens Raymond C — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 53,454 @ $20.99 · Grant/award (A): 824 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | FMR LLC — 10% owner | Sale (S): 465 (derivative) @ $82.10 · Sale (S): 330 (derivative) @ $83.35 · Sale (S): 552 (derivative) @ $84.22 · Sale (S): 20 (derivative) @ $85.04 · Sale (S): 5,477 (derivative) @ $82.10 · Sale (S): 3,880 (derivative) @ $83.35 · +2 more | EDGAR |
| 2025-12-10 | 4 | FMR LLC — 10% owner | Sale (S): 709 (derivative) @ $92.52 · Sale (S): 183 (derivative) @ $94 · Sale (S): 475 (derivative) @ $94.61 · Sale (S): 1,414 (derivative) @ $61.05 · Sale (S): 1,320 (derivative) @ $61.45 · Sale (S): 8,337 (derivative) @ $92.52 · +4 more | EDGAR |
| 2025-09-22 | 4 | Coll Crespo Blas — CHIEF MEDICAL OFFICER | Tax withholding (F): 8,106 @ $7.74 | EDGAR |
| 2025-09-22 | 4 | Hall Ashley — Chief Development Officer | Tax withholding (F): 6,021 @ $7.74 | EDGAR |
| 2025-08-20 | 4 | Ma Yingli — CHIEF TECHNOLOGY OFFICER | Tax withholding (F): 4,470 @ $6.84 | EDGAR |
| 2025-08-20 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 12,846 @ $6.84 | EDGAR |
| 2025-08-01 | 4 | FMR LLC — 10% owner | Sale (S): 26,310 (derivative) @ $17.87 | EDGAR |
| 2025-07-03 | 4 | Coll Crespo Blas — CHIEF MEDICAL OFFICER | Tax withholding (F): 1,233 @ $7.92 · Grant/award (A): 7,992 @ $0 · Tax withholding (F): 1,434 @ $6.84 · Grant/award (A): 429 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Ma Yingli — CHIEF TECHNOLOGY OFFICER | Tax withholding (F): 1,824 @ $7.92 · Grant/award (A): 24,459 @ $0 | EDGAR |
| 2025-07-03 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 6,441 @ $7.92 · Grant/award (A): 57,078 @ $0 | EDGAR |
| 2025-07-03 | 4 | Yoon Jun — CHIEF FINANCIAL OFFICER | Tax withholding (F): 5,940 @ $7.92 · Grant/award (A): 39,606 @ $0 · Tax withholding (F): 7,089 @ $6.84 · Grant/award (A): 831 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Stevens Raymond C — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 12,495 @ $7.92 · Grant/award (A): 89,697 @ $0 · Tax withholding (F): 16,050 @ $6.84 · Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Waldstreicher Joanne — Director | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Russell Angus C. — Director | Grant/award (A): 42,833 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | TETLOW SHARON — Director | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | WELCH DANIEL G — Director | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | DOBMEIER ERIC — Director | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | LOVE TED W — Director | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Lin Xichen — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 80,829 @ $0 · Grant/award (A): 196,386 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Coll Crespo Blas — Chief Medical Officer | Grant/award (A): 116,988 @ $0 · Grant/award (A): 284,241 (derivative) @ $0 · Grant/award (A): 363 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Ma Yingli — CHIEF TECHNOLOGY OFFICER | Grant/award (A): 63,810 @ $0 · Grant/award (A): 155,040 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Yoon Jun — CHIEF FINANCIAL OFFICER | Grant/award (A): 170,166 @ $0 · Grant/award (A): 413,445 (derivative) @ $0 · Grant/award (A): 694 (derivative) @ $0 · Grant/award (A): 821 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Hall Ashley — Chief Development Officer | Grant/award (A): 51,048 @ $0 · Grant/award (A): 124,032 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Stevens Raymond C — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 340,332 @ $0 · Grant/award (A): 826,890 (derivative) @ $0 | EDGAR |
Recent 8-K events — Structure Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2025-12-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GPCR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →